Investor Alert: UroGen Pharma Class Action Lawsuit
Bragar Eagel & Squire, P.C. is a law firm encouraging investors who experienced losses in UroGen Pharma (URGN) to reach out and discuss potential options. If you acquired shares during the outlined period and wish to understand your legal rights, now is the time to act.
What Investors Should Know
If you purchased or acquired securities in UroGen Pharma between July 27, 2023 and May 15, 2025, it is crucial to reach out and explore your options. A legal team from Bragar Eagel & Squire stands ready to assist you. Call to discuss how you can proceed and what this means for your investments.
Class Action Details Explained
The class action lawsuit against UroGen Pharma was filed in a U.S. District Court. This lawsuit is on behalf of individuals and organizations who purchased UroGen securities within the specified time frame. Investors needing to act must submit their applications to the court by July 28, 2025, to be considered for lead plaintiff status.
Understanding UroGen's Operations
UroGen is focused on developing and commercializing effective treatments for specialty cancers. One of their primary projects is UGN-102, an innovative treatment designed to address low-grade non-muscle invasive bladder cancer.
Allegations in the Lawsuit
The lawsuit presents serious allegations against UroGen. It claims that misleading statements were made by the company's representatives, particularly regarding the ENVISION clinical study for UGN-102. The specifics of the allegations include that the study was improperly designed and lacked critical controls that are essential for demonstrating drug effectiveness.
The Impact of Regulatory Actions
On May 16, 2025, the FDA released guidance stating that the study did not include a concurrent control arm, making it hard to draw reliable conclusions about the therapy's effectiveness. This led to significant stock price declines for UroGen, suggesting that investors suffered losses due to the unmet expectations created by UroGen's claims.
Subsequent Developments and Stock Reaction
Further complicating matters, on May 21, 2025, the FDA’s advisory committee voted against the UGN-102 NDA, leading to another significant drop in the company's stock price. These developments highlight the volatility and risk associated with investments in UroGen Pharma and the potential repercussions for shareholders.
Reaching Out for Help
If you are an investor who faced losses and are in need of guidance, Bragar Eagel & Squire is here to assist you. They can be reached directly at (212) 355-4648 for a comprehensive assessment of your situation.
About Bragar Eagel & Squire, P.C.
This law firm has established a reputation for representing both individual and institutional investors across various legal matters in federal and state courts. They continue to uphold strong advocacy within securities litigation, and they’re eager to help investors navigate these challenges.
Contact Information for Investors
For more detailed information, feel free to reach out to Bragar Eagel & Squire via phone or email to discuss your concerns. They are committed to providing support without any upfront costs, making it accessible for you to understand your legal standing.
Frequently Asked Questions
1. What is the timeline for filing a claim in the UroGen lawsuit?
Investors have until July 28, 2025, to apply to be appointed as lead plaintiff in the lawsuit.
2. What should I do if I invested in UroGen Pharma?
If you lost money on your investment in UroGen Pharma during the specified timeframe, you should reach out to a securities attorney for legal guidance.
3. How does the class action lawsuit process work?
A class action lawsuit allows multiple investors with similar claims to consolidate their cases against a defendant, which can strengthen their position.
4. Are there any costs associated with pursuing the lawsuit?
No. Bragar Eagel & Squire typically works on a contingency fee basis, meaning you only pay if you win.
5. How can I stay updated on the UroGen lawsuit?
By contacting Bragar Eagel & Squire or monitoring legal news, you can stay informed about developments in the case.
